Auro Laboratories Ltd (AUROLAB) is currently trading at 259.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Auro Laboratories Ltd specializes in the manufacturing of generic Active Pharmaceutical Ingredients (APIs), with a primary focus on anti-diabetic medications like Metformin HCL. The company is serving international markets, exporting a significant portion of its production to regions such as South East Asia, the Middle East, and Europe. With a current capacity of 1800 MTPA for Metformin HCL, Auro Laboratories plans to double this capacity, signaling a strong growth trajectory. The company's manufacturing facilities are ISO 9001:2000 and WHO-cGMP certified, which reinforces their commitment to high-quality production standards.

Over the past 52 weeks, Auro Laboratories Ltd has traded between a low of ₹159.00 and a high of ₹317.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Auro Laboratories Ltd has a market capitalization of approximately 160.02. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Auro Laboratories Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 34.12 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 160.02 Cr, Auro Laboratories Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Auro Laboratories Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Auro Laboratories Ltd is 34.12. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.